Cash from Financing (Quarterly) Chart

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
September 30, 2026 57.26M
June 30, 2026 13.17M
March 31, 2026 5.075M
December 31, 2025 107.95M
September 30, 2025 -0.121M
June 30, 2025 -0.119M
March 31, 2025 -0.061M
December 31, 2024 0.104M
September 30, 2024 -0.066M
June 30, 2024 37.12M
March 31, 2024 0.029M
December 31, 2023 0.00
September 30, 2023 -0.001M
June 30, 2023 0.00
March 31, 2023 -0.029M
December 31, 2022 0.00
September 30, 2022 0.00
June 30, 2022 0.00
March 31, 2022 -0.21M
December 31, 2021 0.755M
Date Value
September 30, 2021 97.26M
June 30, 2021 0.004M
March 31, 2021 0.014M
December 31, 2020 0.00
September 30, 2020 -0.385M
June 30, 2020 48.78M
March 31, 2020 25.60M
December 31, 2019 -0.019M
September 30, 2019 1.254M
June 30, 2019 1.26M
March 31, 2019 12.32M
December 31, 2018 -0.04M
September 30, 2018 -0.067M
June 30, 2018 1.008M
March 31, 2018 15.00M
December 31, 2017 17.90M
September 30, 2017 0.00
June 30, 2017 0.02M
March 31, 2017 29.85M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Indaptus Therapeutics, Inc. 20.30M
Cue Biopharma, Inc. 50.63M
Yarrow Bioscience, Inc. 265.03M
Faeth Therapeutics, Inc. 0.104M
Pyxis Oncology, Inc. 38.58M